Published in Vaccine Weekly, December 16th, 2009
An innovative treatment for HIV patients developed by McGill University Health Centre researchers has passed its first clinical trial with flying colours. The new approach is an immunotherapy customized for each individual patient, and was developed by Dr. J-P. Routy from the Research Institute of the MUHC in collaboration with Dr. R. Sekaly from the Universite de Montreal. "This is a vaccine made for the individual patient - an "haute couture" therapy, instead of an off-the-rack treatment" said Dr Routy.
By "priming" the immune system, as with a vaccine, to fight the specific strain of HIV/AIDS infecting a given...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2009-12-16)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.